Clinical Trials Logo

Thyroid Diseases clinical trials

View clinical trials related to Thyroid Diseases.

Filter by:

NCT ID: NCT05696548 Active, not recruiting - Clinical trials for Anaplastic Thyroid Cancer

Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)

Start date: July 2, 2019
Phase: Phase 2
Study type: Interventional

This study is an open-label phase 2 study to evaluate the safety and efficacy of Nivolumab plus Lenvatinib in patients with unresectable anaplastic thyroid cancer.

NCT ID: NCT05684029 Completed - Thyroid Cancer Clinical Trials

Near-Infrared Autofluorescence With PTH Test Strip as an SOP of Parathyroid in Thyroid Surgery

PTFINDER
Start date: November 1, 2022
Phase:
Study type: Observational

This is a prospective study aiming to establish near-infrared autofluorescence technology and PTH test strip as a standardized process for finding and identifying parathyroid glands in thyroid surgery.

NCT ID: NCT05683496 Recruiting - Thyroid Eye Disease Clinical Trials

Efficacy and Safety of Lonigutamab in Subjects With Thyroid Eye Disease (TED)

TED
Start date: February 14, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

Phase 1/2, multicenter, multiple dose clinical study designed to evaluate lonigutamab in subjects with TED.

NCT ID: NCT05680376 Completed - Clinical trials for Recurrent Miscarriage

Thyroid Hormone Values and Anti-thyroid Peroxidase Antibody Positivity in Recurrent Pregnancy Loss

Start date: January 1, 2018
Phase:
Study type: Observational

The aim of this study is to compare the thyroid hormone values and anti-thyroid peroxidase (anti-TPO) levels of women with a diagnosis of recurrent pregnancy loss (RPL) and healthy pregnancies. The primary objective is to find out the relationship between recurrent pregnancy loss with thyroid hormone levels and anti-TPO positivity.

NCT ID: NCT05678374 Recruiting - Autoimmune Diseases Clinical Trials

Exploring Immunological Markers Associated With Mental Fatigue in Graves' Disease

Start date: October 1, 2019
Phase:
Study type: Observational

Mental fatigue occurs in many diseases and the reasons are mostly unknown. The investigators hypothesize that remaining mental fatigue after restored hyperthyroidism in Graves' disease is an autoimmune complication. The aim of this study is to explore immunological markers possibly associated with mental fatigue in Graves' disease, which the investigators plan to validate in another study (ImmunoGraves wp 2). Using a cross-sectional study design, mental fatigue is scored using a questionnaire to find 60 patients with and 60 without mental fatigue 15-60 months after diagnosis of Graves disease. The patients and 60 thyroid healthy controls without mental fatigue are assessed for thyroid hormones, quality of life, anxiety and depression, self-evaluated stress, coping strategies, eye symptoms and background variables. SciLifeLab in Stockholm, the national facility for autoimmune profiling, has pre-set large arrays including 42000 human proteins. Serum and cerebrospinal fluid will be separately pooled and analysed for a subgroup of patients with or without mental fatigue and for a subgroup of the control group. Proteins that preferably bind to antibodies in sera and/or cerebrospinal fluid from Graves' patients with mental fatigue in comparison to non-mental fatigue patients, will be screened against the Human Protein Atlas and the Allen brain map to identify those proteins that are expressed in the brain. Antibodies at higher concentration in the mental fatigue pools compared to the group without mental fatigue will be selected for further analyses on an individual level in the whole cohort together with antibodies targeting g-protein coupled receptors, thyroid autoantibodies, cytokines and biomarkers indicating organic and structural nerve damage.

NCT ID: NCT05677581 Recruiting - Thyroid Function Clinical Trials

Longitudinal Study on the Influence of Iodine Nutrition Status on Thyroid Function of Childbearing Age Women During Pregnancy and 6 Weeks Postpartum

Start date: November 15, 2023
Phase:
Study type: Observational

The goal of this observational study is to provide a reference for formulating individual appropriate iodine intake programs for women during pregnancy and postpartum and improving the monitoring and evaluation system of maternal iodine nutrition status. The main questions it aims to answer are: - To analyse the longitudinal changes of urinary iodine, urinary iodine/creatinine ratio, thyroid function and related factors in different periods of early, middle, late pregnancy and 6 weeks postpartum in Beijing area. - To explore the relationship between iodine nutrition status and the changes of thyroid function and to further clarify the effect of iodine nutrition status on thyroid function of women of childbearing age during pregnancy and postpartum in combination with dietary intake of iodine questionnaire. Participants will be detected there thyroid function, the level of median urinary iodine and urinary iodine/creatinine. Researchers will compare healthy women of childbearing age served as the control group in the same period.

NCT ID: NCT05675605 Recruiting - Neoplasms Clinical Trials

A Study of TY-1091 in Patients With Advanced Solid Tumors

Start date: April 24, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of TY-1091 administered orally in participants with medullary thyroid cancer (MTC), RET-altered NSCLC and other RET-altered solid tumors.

NCT ID: NCT05668962 Recruiting - Thyroid Cancer Clinical Trials

Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC

Start date: March 1, 2023
Phase: Phase 2
Study type: Interventional

This research is being done to determine the efficacy of selpercatinib to restore radioactive iodine (I-131) uptake and allow for I-131 treatment in people with RET fusion-positive radioiodine-refractory thyroid cancer. This research study involves the study drug selpercatinib in combination with standard of care treatments, I-131 and thyrotropin alfa (rhTSH).

NCT ID: NCT05660954 Recruiting - Clinical trials for Differentiated Thyroid Cancer

Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.

CABOTHYROID
Start date: May 25, 2023
Phase: Phase 2
Study type: Interventional

CABOTHYROID is a prospective, exploratory, biomarker-focused, phase II, single-arm, non-randomized, non-blinded, investigator-initiated study of cabozantinib in patients with previously treated advanced radioactive-iodine refractory

NCT ID: NCT05659186 Recruiting - Thyroid Cancer Clinical Trials

PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer

Start date: December 30, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of PD-1 inhibitor and anlotinib combined with multimodal radiotherapy for the second-line treatment of recurrent or metastatic anaplastic thyroid cancer.